Company news
Revolution Medicines, Inc. news in 2021
Revolution Medicines, Inc.'s news releases, calls and decks from 2021, newest first.
Revolution Medicines to Participate in 4th Annual Evercore ISI HealthCONx Conference
November 23, 2021
Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress
November 9, 2021
Revolution Medicines to Participate in Stifel 2021 Virtual Healthcare Conference
November 7, 2021
Revolution Medicines to Report Financial Results for Third Quarter 2021 After Market Close on November 10, 2021
November 2, 2021
Revolution Medicines to Present New Preclinical Data from RAS(ON) Inhibitor Programs at AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
September 29, 2021
Revolution Medicines to Participate in 3rd Annual RAS-Targeted Drug Development Summit
September 14, 2021
Revolution Medicines to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 6, 2021
Revolution Medicines Reports Second Quarter Financial Results and Update on Corporate Progress
August 10, 2021
Revolution Medicines to Report Financial Results for Second Quarter 2021 After Market Close on August 11, 2021
August 3, 2021
Revolution Medicines Announces Publication of Scientific Paper Describing Novel Class of Anti-Tumor Compounds Targeting mTORC1
June 23, 2021
Revolution Medicines to Host Science Talk Webcast Highlighting Learnings from Recent Preclinical and Clinical Studies of RAS Inhibitors
June 9, 2021
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 1, 2021
Revolution Medicines to Participate in Cowen 2nd Annual Virtual Oncology Innovation Summit
May 17, 2021
Revolution Medicines Reports First Quarter Financial Results and Update on Corporate Progress
May 9, 2021
Revolution Medicines Highlights Slate of Diverse Board of Directors Nominees for Upcoming 2021 Annual Shareholder Meeting
May 2, 2021
Revolution Medicines Announces Dosing of First Patient in Phase 1/1b Clinical Study of RMC-5552 in Patients with Advanced Solid Tumors
April 20, 2021
Revolution Medicines Announces Six Presentations at the American Association for Cancer Research Annual Meeting 2021
March 10, 2021
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
March 1, 2021
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
February 17, 2021
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 7, 2021
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 2, 2021
Revolution Medicines Announces Proposed Public Offering of Common Stock
January 31, 2021
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 4, 2021